Abivax S.A. (AAVXF)
AAVXF is quoted over the counter, not listed on an exchange. Abivax S.A. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | AAVXF, quoted over the counter |
| SEC CIK | 0001956827 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | Paris |
| Incorporated in | France |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-23 |
| Cash and burn | 516.7M EUR cash; operating cash flow -40.3M EUR a quarter. | Report 2025-12-31 |
| Shares outstanding | 78,536,412 (2025-12-31); 63,347,837 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-07-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PRICEWATERHOUSECOOPERS AUDIT, NEUILLY-SUR-SEINE, France | PCAOB Form AP 2026-04-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -336.1M EUR | -161.1M EUR | 516.7M EUR | No debt tags | Needs four quarters | 20-F 2026-03-23 |
| FY 2024 2024-12-31 | Not filed | -176.2M EUR | -154.1M EUR | 144.2M EUR | No debt tags | Needs four quarters | 20-F 2026-03-23 |
| FY 2023 2023-12-31 | Not filed | -147.7M EUR | -97.1M EUR | 251.9M EUR | No debt tags | Needs four quarters | 20-F 2026-03-23 |
| FY 2022 2022-12-31 | Not filed | -60.7M EUR | -53.9M EUR | 26.9M EUR | No debt tags | Needs four quarters | 20-F 2025-03-24 |
| FY 2021 2021-12-31 | Not filed | -42.5M EUR | -45.0M EUR | 60.7M EUR | No debt tags | Needs four quarters | 20-F 2024-04-05 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-07-02 |
| Latest annual report | 20-F | 2026-03-23 |
| Latest quarterly / interim | 6-K | 2026-09-21 |
Source: SEC EDGAR submissions feed, 106 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier